Cellectis S.A. CLLS
We take great care to ensure that the data presented and summarized in this overview for Cellectis S.A. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CLLS
View all-
Long Focus Capital Management, LLC San Juan, PR4.62MShares$7.25 Million0.36% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$2.9 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.26 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL1.44MShares$2.26 Million0.0% of portfolio
-
Baillie Gifford & CO694KShares$1.09 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$356,1930.0% of portfolio
-
Kbc Group Nv163KShares$256,6110.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC92.4KShares$145,0240.0% of portfolio
-
Morgan Stanley New York, NY91.5KShares$143,6940.0% of portfolio
-
Two Sigma Investments, LP New York, NY33.4KShares$52,4560.0% of portfolio
Latest Institutional Activity in CLLS
Top Purchases
Top Sells
About CLLS
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Insider Transactions at CLLS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|